Genomic Enterprise

 
Mack GS & Marshall A (March, 2010). Interviewed and cited in a Feature article about cancer metastasis and drug development in the journal Nature Biotechnology entitled: "Lost in migration." Nat. Biotechnology. 28 (3): 214–229.

 
Costa FF (February, 2010). Non-coding RNAs: old molecules, new functions - shifting paradigms in genomics? BioForum Europe. In press.
 

Sredni  ST, Bonaldo MF, Costa FF, Chiang-Ching H, Hamm C, Rajaram V, Tomita T, Goldman S, Bischof JM, Soares MB (December, 2009). Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Child’s Nervous System. 26, 279-283. 

 
Costa FF (November, 2009). Genomics, epigenomics and personalized medicine - a bright future for drug development?
BioForum Europe. Vol. 13, 29-31.

Hamm CA,  Xie H,  Costa FF,  Vanin EF, Seftor EA, Sredni ST,  Bischof JM,  Bonaldo MF,  Hendrix MJC, Soares MB. (December, 2009). Global demethylation of rat chondrosarcoma cells after treatment with 5-Aza-2-deoxycytidine results in increased tumorigenicity. PLoS One. 4 (12): e8340.
 

Ramos EAS, Camargo AA,  Prado KB,  Slowik R,  Cavalli IJ, Ribeiro ESF, Pedrosa FO, Souza EM, Costa FF and  Klassen G (October, 2009). Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer. 10: 23.

Lewandowska MA, Costa FF, Bischof JM, Williams SH,  Soares MB, Harris A (September, 2009). Multiple mechanisms influence regulation of the CFTR gene promoter. American Journal of Cell and Respiratory Biology. In press.

 
Costa FF,  Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, Arndt K, Bonaldo MF, Soares MB, Hendrix MJ (December, 2009). Epigenetically Reprogramming Metastatic Tumor Cells with an Embryonic Microenvironment. Epigenomics. Vol. 1, 2: 387-398.

 
Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschman D, Seftor RE, Postovit LM, Hendrix MJ. (September, 2009). Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Research. 69: 7131-7134.

 
Verbisck NV, Costa ET, Costa FF, Cavalher FP, Costa MDM, Muras A, Paixão VA, Moura RP, Granato MF, Ierardi DF, Machado T, Melo F, Ribeiro KB, Cunha IW, Lima VCC, Maciel MS, Carvalho AL, Soares F, Zanata SM, Sogayar MC,Chammas R, Camargo AA (June, 2009). ADAM23 negatively modulates αvβ3 integrin activation during metastasis. Cancer Research. 69: 5546-5552.

 
Costa FF (April, 2009). Non-coding RNAs and new opportunities for the private sector. Drug Discovery Today. 14 (9-10): 446 - 452.

 
Seniski GG, Camargo AA, Ierardi DF, Ramos EAS, Grochoski M, Ribeiro ESF, Cavalli IJ, Pedrosa FO, de Souza EM, Zanata SM, Costa FF, Klassen G (March, 2009). ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 9 (1): 80.

Passetti F, Ferreira CG, Costa FF (February, 2009). The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J. 9 (1): 1-13.

 
Maguire CA, Meijer DH, Leroy SG, Tierney LA, Broekman MLD, Costa FF, Breakefield XO, Stemmer-Rachamimov A,  Sena-Esteves M (August, 2008) . Preventing growth of brain tumors by creating a zone of resistance. Molecular Therapy.16(10):1695-1702.

 
Costa FF (February, 2008). Non-coding RNAs, epigenetics and complexity. Gene: 410 (1): 9-17.

 
Wurdinger T, Costa FF (November, 2007). An expert commentary entitled “The potential of miRNA modulators as targeted oncology therapies - an update”. Spectrum Newspaper for Pharmaceutical Industry Dynamics - Dealmaking and Financing: 15-26, 15-27.

Wurdinger T, Costa FF (October, 2007). Molecular therapy in the microRNA era. Pharmacogenomics J: 7(5):297-304.

Postovit LM, Costa FF, Bischof JM, Seftor EA, Wen B, Seftor RE, Feinberg AP, Soares MB, Hendrix MJ (July, 2007).The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J Cell Biochem: 101(4):908-17.

 
Mack GS (June, 2007). Interviewed and cited in a feature article in the Nature Biotechnology Journal entitled “MicroRNA gets down to business”. Nat. Biotechnology: 25 (6):.631-638.

Wurdinger T, Costa FF (May, 2007). A spectrum expert commentary entitled “The potential of miRNA modulators as targeted oncology therapies”. Spectrum Newspaper for Pharmaceutical Industry Dynamics: 5-25.

Costa FF, Le Blanc K, Brodin B (March, 2007). Concise review: cancer/testis antigens, stem cells and cancer. Stem Cells: 25 (3):707-11.

Costa FF (January, 2007). Non-coding RNAs: lost in translation? Gene: 386 (1-2):1-10.

Costa FF, Paixão VA, Cavalher FP, Ribeiro KB, Cunha IW, Rinck JA, O'Hare M, Mackay A, Soares FA, Brentani RR, Camargo AA (March, 2006). SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genetics and Cytogenetics: 165 (2):135-143.

 
Costa FF (September, 2005). Non-coding RNAs: new players in eukaryotic biology. Gene: 357(2):83-94.

Costa FF (August, 2005). Non-coding RNAs: functional molecules or a quality control error? A comment on: BabaK T, Blencowe BJ and Hughes TR. A systematic search for new mammalian noncoding RNAs indicates little conserved intergenic transcription. BMC Genomics: 6: 104.

Costa FF, Colin C, Shinjo SM, Zanata SM, Marie SK, Sogayar MC, Camargo AA (June, 2005). ADAM23 methylation and expression analysis in brain tumors. Neuroscience Letters: 380 (3): 260-4.

Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, Sasahara RM, Sogayar MC, Zanata SM, Mackay A, O'Hare M, Soares F, Simpson AJ, Camargo AA (February, 2004). Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene: 23 (7):1481-8.

Abrantes EF, Pires EG, Carvalho AF, Costa FF, Savino W, Reis LF (June, 2003). Identification, structural characterization and tissue distribution of Tsg-5: a new TNF-stimulated gene. Genes and Immunity: 4 (4):298-311.

Fabricio F. Costa and Anamaria A. Camargo (2003). Bases da Oncologia 2nd edition - Chapter 5: Oncogenes and Tumor Supressor Genes (Book Chapter).

 
Gontijo NF,  Almeida-Silva S, Costa FF, Mares-Guia ML, Williams P, Melo MN (November, 1998). Lutzomyia longipalpis: pH in the gut, digestive glycosidases, and some speculations upon Leishmania development. Experimental Parasitology. 90 (3): 212-219.